Cytocom, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by SALUCK RANDY S., was filed 27 Feb 2015.
Cytocom, Inc.: what insiders have been doing
Every trade that managers of Cytocom, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. No insider at Cytocom, Inc. has published a filing in the past twelve months. The most recent one dates from 28 October 2021.
Our records for Cytocom, Inc. go back to 2006, with 26 purchases and 191 sales on the open market in total.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
- 60,000 shares0Common Stock, par value $0.005 per shareSEC:0001437749-21-024527:0
- 60,000 shares0Common Stock, par value $0.005 per shareSEC:0001437749-21-023899:0
- 60,000 shares0Common Stock, par value $0.005 per shareSEC:0001437749-21-023900:0
- 100,000 shares0Common Stock, par value $0.005 per shareSEC:0001437749-21-022936:0
- 296,609 shares0Common Stock, par value $0.005 per shareSEC:0001437749-21-018563:0
- 141,370 shares0Common Stock, par value $0.005 per shareSEC:0001437749-21-017950:0
- 101,579 shares0Common Stock, par value $0.005 per shareSEC:0001437749-21-017952:0
- 24,378 shares0Common Stock, par value $0.005 per shareSEC:0001437749-21-017953:0
- 60,947 shares0Common Stock, par value $0.005 per shareSEC:0001437749-21-017951:0
- 10,000 shares@ US$3.00100.0% of flowCommon Stock, par value $0.005 per shareSEC:0001437749-21-017452:0
- 1,891 shares@ US$3.42Common Stock, par value $0.005 per shareSEC:0001209191-15-019946:0Canonical exit: 26 May 2015 (T+90)
- 37,947 shares@ US$0.30Common StockSEC:0001209191-15-003667:0
- 62,500 shares@ US$0.30Common StockSEC:0001209191-15-003673:0
- 22,978 shares@ US$0.68Common Stock, par value $0.005 per shareSEC:0001209191-14-021060:0
- 10,487 shares0Common Stock, par value $0.005 per shareSEC:0001171843-13-002567:0
- 14,472 shares0Common Stock, par value $0.005 per shareSEC:0001171843-13-002570:0
- 15,939 shares0Common Stock, par value $0.005 per shareSEC:0001171843-13-002569:0
- 10,102 shares0Common Stock, par value $0.005 per shareSEC:0001171843-13-002568:0
- 6,210 shares@ US$1.61Common Stock, par value $0.005 per shareSEC:0001171843-13-002224:0Canonical exit: 19 Aug 2013 (T+90)
- 3,500 shares@ US$1.60Common Stock, par value $0.005 per shareSEC:0001171843-13-002172:0Canonical exit: 15 Aug 2013 (T+90)
- 3,700 shares@ US$1.56Common Stock, par value $0.005 per shareSEC:0001171843-13-001036:0Canonical exit: 13 Jun 2013 (T+90)
- 2,316 shares@ US$2.60Common Stock, par value $0.005 per shareSEC:0001171843-12-003463:0Canonical exit: 20 Dec 2012 (T+90)
- 1,000 shares@ US$1.61Common stock, par value $0.005 per shareSEC:0001171843-12-002469:0Canonical exit: 30 Sept 2012 (T+90)
- 300 shares@ US$3.14Common Stock, par value $0.005 per shareSEC:0001171843-12-002467:0Canonical exit: 14 Jun 2012 (T+90)
- 300 shares@ US$3.15Common Stock, par value $0.005 per shareSEC:0001171843-12-002467:1Canonical exit: 14 Jun 2012 (T+90)
25 of 254 declarations
About Cytocom, Inc.
Cytocom, Inc. (ticker: CBLI) was a U.S.-based biopharmaceutical company whose investment case was centered on immune-modulation and related therapeutic development. For French-speaking investors, the key market reference is that CBLI traded on NASDAQ in the United States, placing it within the highly speculative small-cap biotech universe rather than a mature commercial pharma peer group. SEC materials describe Cytocom as a development-stage company focused on building and advancing a portfolio of therapeutic candidates, with an emphasis on immune homeostasis, inflammation-related disease areas, and oncology-adjacent applications. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1318641/000143774921019964/cbli20210630_10q.htm?utm_source=openai))
The company’s history is closely tied to corporate restructuring. In July 2021, Cleveland BioLabs completed its merger with Cytocom, and the combined company began trading under the CBLI symbol on NASDAQ. Subsequent SEC disclosures show that the corporate identity associated with Cytocom was later changed again to Statera Biopharma, underscoring that Cytocom’s standalone branding was part of a transitional phase in a broader reorganization. In other words, CBLI is best understood as a reorganized biotech platform rather than a long-established operating pharmaceutical franchise. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1318641/000143774922006873/cbli20220220_424b5.htm?utm_source=openai))
Read moreShow less
Operationally, Cytocom’s model was built around research, clinical development, and the potential commercialization of pre-revenue drug candidates. SEC filings reference activities conducted through subsidiaries such as ImQuest Life Sciences, ImQuest BioSciences, ImQuest Pharmaceuticals, and Lubrinovation, which points to a portfolio structure typical of early-stage biotechnology companies. The company’s disclosures indicate exposure to candidates and programs targeting immune regulation, with the broader goal of translating scientific assets into regulated therapeutic products. That profile implies a business driven by pipeline milestones rather than by recurring product sales. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1318641/000143774921019964/cbli20210630_10q.htm?utm_source=openai))
From a competitive standpoint, Cytocom operated in one of the most crowded and capital-intensive areas of healthcare. Its competitive position depended less on scale and more on scientific differentiation, intellectual property, clinical data, and the ability to secure financing or strategic partnerships. Compared with large-cap biopharma groups, Cytocom had limited commercial infrastructure and a much higher dependence on external capital, making the stock especially sensitive to trial updates, balance-sheet changes, and insider transaction filings under SEC Form 4. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1318641/000143774921017701/ex_268327.htm?utm_source=openai))
Recent developments available in the SEC record are more about corporate transformation than about commercial launch execution. For investors, that means the most relevant diligence points are the state of the pipeline, financing needs, and the significance of any insider activity disclosed on Form 4. Overall, Cytocom was a United States biotech issuer quoted on NASDAQ whose story was defined by restructuring, development-stage assets, and high execution risk rather than by an established marketed-product base. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1318641/000143774921019964/cbli20210630_10q.htm?utm_source=openai))
